A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients

Phase 2

Completed

• Conditions: Atopic Dermatitis
• Interventions: Drug: Hemay808

• Registration Number: NCT04352595
• Lead Sponsor: Tianjin Hemay Pharmaceutical Co., Ltd

Brief Summary

Assess Hemay808 concentration of 1%/3%/7% for treatment of mild and moderate adult atopic dermatitis patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-03-20
• Study First Submitted QC: 2020-04-15
• Study First Posted: 2020-04-20
• Study Start: 2020-04-24
• Primary Completion: 2021-02-28
• Study Completion: 2021-04-02
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-29
• Last Update Posted: 2024-03-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 148

Inclusion Criteria

• ≥18 years old and ≤65 years old, gender is not limited;
• It met the diagnostic criteria for atopic dermatitis (AD) of Hanifin&Rajka, and the history of AD before screening was ≥6 months;
• The investigator's overall score (IGA) at the screening period/baseline visit was 2-3;
• The skin lesion area of atopic dermatitis (excluding scalp lesions) is 3%-20% of body surface area (BSA) and suitable for local treatment;
• During the study period and within 3 months after the last administration, fertile female subjects and male subjects who did not receive vasectomy were required to take effective contraceptive measures;
• Those who have full knowledge of the test, participate in the test voluntarily and sign the informed consent.

Exclusion Criteria

• The lesion area of AD is infected and requires local or systematic treatment with anti-infective drugs, or external administration of strong or potent glucocorticoids (see annex 4) or systematic administration of glucocorticoids to control AD Useing of systemic glucocorticoids and/or immunosuppressants within 4 weeks; Or sunbathing, phototherapy (including ultraviolet therapy, photochemotherapy, etc.); Or systematic use of traditional Chinese medicine or natural medicine for the purpose of treating atopic dermatitis;

• The AD lesion area was marked, tattooed, or hyperpigmented, and was judged by the investigator to interfere with the evaluation of the response to the study's drug therapy;

• Previous use of systemic or local pde-4 inhibitors;

• Suffering from clinically significant active systemic infections;

• 2 times the normal upper limit of ALT or AST >, or the normal upper limit of Cr and > of renal function (study allowed 1 reexamination, excluded if still not meeting the inclusion requirements);

• Unwilling to limit their excessive uv exposure during the study period (e.g., sunbathing and/or tanning devices);

• Received the following treatment in the limited time period prior to baseline evaluation:

  1. . Received biologic therapy (including intravenous immunoglobulin) within 12 weeks or 5 half-lives, whichever is greater;
  2. . Use of systemic glucocorticoids and/or immunosuppressants within 4 weeks; Or sunbathing, phototherapy (including ultraviolet therapy, photochemotherapy, etc.); Or systematic use of traditional Chinese medicine or natural medicine for the purpose of treating atopic dermatitis;
  3. . The following treatment was administered within 2 weeks: systemic anti-infective drugs (both oral and intravenous); Or local use of glucocorticoid or local use of calcineurin inhibitor; Local use of traditional Chinese medicine or natural medicine for the purpose of treating atopic dermatitis; Or other topical drugs for the treatment of atopic dermatitis [zinc oxide oil (paste), black bean oil ointment, doxepin cream, etc.];
  4. . Local anti - microbial preparation was used within 1 week;

• Suffering from serious diseases of the central nervous system, cardiovascular system, respiratory system, liver, kidney, gastrointestinal system, urinary system, endocrine system or blood system, and the researcher believes that may confused result or affect the safety of the subjects;

• Suffering from a serious mental illness or other condition that affects research compliance and may interfere with the conduct of clinical trials;

• A history of malignant tumor;

• With a history of severe allergic reactions to skin topical preparations (including angioedema, allergic reactions, etc.) or known allergic reactions to Hemay808 accessories;

• Screening people who had a long history of drug abuse or alcohol abuse in the first 6 months;

• Female subjects who are suspected to be pregnant, lactating or preparing for pregnancy during the test;

• The subject plans to undergo surgery requiring hospitalization or surgery during his or her participation in the study;

• Those who participated in clinical studies of other drugs/devices and used experimental drugs/devices within the last 3 months of randomized enrollment;

• Other conditions made the researchers considered inappropriate for the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
3% Hemay808	Hemay808	-
vehicle	Hemay808	-
1% Hemay808	Hemay808	-
7% Hemay808	Hemay808	-

Primary Outcome Measures

Name	Time	Method
The change in the EASI score relative to the baseline.	Day 29	EASI Clinical Signs Severity Sum Score change from Baseline at Day 29

Secondary Outcome Measures

Name	Time	Method
The percentage of subjects achieving Investigator's Global Score (IGA) response which improvement ≥ 2 from baseline.	Day 8, Day 15, Day 22, Day 28	The IGA is a validated assessment instrument used in clinical studies to rate the severity of AD globally.
The percentage of subjects achieving EASI90, EASI75, EASI50.	Day 8, Day 15, Day 22, Day 28	EASI Clinical Signs Severity Sum Score ≥50%, 75%, 90% improvement from baseline.
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score.	Day 8, Day 15, Day 22, Day 28	The DLQI is a general dermatology questionnaire that consists of 10 items that assess participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). It has been extensively used in clinical trials for AD. The DLQI is a psychometrically valid and reliable instrument that has been translated into several languages, and the DLQI total scores have been shown to be responsive to change. The minimally important difference for the DLQI has been estimated as a 2-5 point change from baseline. Each item is scored as "very much (3)", "a lot (2)", "a little (1)" and "not at all (0)". The score can range from 0 to 30. The higher values represent the worse dermatology life quality
The change in the IGA score relative to the baseline.	Day 8, Day 15, Day 22, Day 28	Change From Baseline in the IGA Clinical Signs Severity Sum Score.
The percentage of subjects achieving Investigator's Global Score (IGA) score 0-1.	Day 8, Day 15, Day 22, Day 28	The IGA is a validated assessment instrument used in clinical studies to rate the severity of AD globally.
Absolute change in weekly average of daily peak Pruritus Numerical Rating Scale (NRS).	Day 8, Day 15, Day 22, Day 28	Range of 0 (No itch) to 10 (Worst imaginable itch)
The percentage of AD invoved BSA (body surface area) change From Baseline.	Day 8, Day 15, Day 22, Day 28	AD invoved body surface area.

Trial Locations

Locations (2)

Dermotology hospital, Chinese academy of medical science; 🇨🇳 Nanjing, Jiangsu, China

Ningbo second hospital; 🇨🇳 Ningbo, Zhejiang, China